Drug Profile

Trastuzumab deruxtecan companion diagnostic - Guardant Health

Alternative Names: trastuzumab deruxtecan Guardant360® CDx companion diagnostic

Latest Information Update: 19 Dec 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

19 Dec 2025 Trastuzumab deruxtecan companion diagnostic is still registered for Non-small cell lung cancer (Diagnosis, Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater, Recurrent) in Japan
19 Dec 2025 Trastuzumab deruxtecan companion diagnostic is still registered for Non-small cell lung cancer (Diagnosis, Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater, Recurrent) in USA
05 Sep 2023 Registered for Non-small cell lung cancer (Diagnosis, Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater, Recurrent) in Japan (unspecified route)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com